Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Icatibant Acetate

FDA-approved product (injectable, subcutaneous), marketed as Firazyr, Icatibant Acetate.

Registered studies
33
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Icatibant Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angioedema
  • Hereditary angioedema

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in hereditary angioedema
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Icatibant Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Icatibant Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)

    NCT00500656 · start 2005-03-01

    Registered record
    Registry ID
    NCT00500656
    Conditions
    Hereditary Angioedema
    Interventions
    Icatibant; Tranexamic Acid; Oral Placebo; S.C. Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-03-01
    Completion
    2006-07-25
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionIcatibant; Tranexamic Acid; Oral Placebo; S.C. Placebo
    PhasePhase 3
    Registry statusCompleted

  • Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

    NCT00097695 · start 2004-12-28

    Registered record
    Registry ID
    NCT00097695
    Conditions
    Angioedema
    Interventions
    Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-12-28
    Completion
    2006-07-17
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngioedema
    InterventionIcatibant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study

    NCT01154361

    Registered record
    Registry ID
    NCT01154361
    Conditions
    Angioedema
    Interventions
    Icatibant (subcutaneous) and plazebo (intravenous); Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngioedema
    InterventionIcatibant (subcutaneous) and plazebo (intravenous); Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)
    PhasePhase 2
    Registry statusCompleted